New in the marketplace

  • PDF / 51,220 Bytes
  • 1 Pages / 592.44 x 751.18 pts Page_size
  • 60 Downloads / 156 Views

DOWNLOAD

REPORT


New in the marketplace The following table contains a summary of product approvals identified in international markets in recent weeks by the drug therapy reporting service Inpharma Weekly. Summarising information selected from over 1600 biomedical publications, this newsletter is produced by Wolters Kluwer Health | Adis and is available in a variety of formats. Generic name (trade name) Cytarabine liposome (DepoCyt®) H5N1 influenza virus vaccine

Company (URL)a Enzon (http://www.enzon.com)

sanofi-pasteur (http://www.sanofipasteur.com) Imidafenacin (Staybla®) Ono (http://www.ono.co.jp) Retapamulin (Altabax™) GlaxoSmithKline (http://www.gsk.com) sanofi-aventis Rimonabant (Acomplia®) (http://www.sanofi-aventis.com) Zoledronic acid (Reclast®) Novartis (http://www.novartis.com) a Product approval information obtained from media releases available

Drugs Ther Perspect 2007; Vol. 23, No. 6

Indication Treatment of lymphomatous meningitis

Country/region US

Prevention of avian influenza

US

Treatment of overactive bladder Japan Treatment of impetigo due to Staphylococcus US aureus or Streptococcus pyogenes infections Treatment of obese and overweight patients Switzerland with at least one cardiovascular risk factor Treatment of Paget’s disease of the bone US on company websites. See websites for further details.